ARTICLE: Ethical and Practical Issues Associated With the Possibility of Using Controlled Human Infection Trials in Developing a Hepatitis C Virus Vaccine
AUTHORS: Andrea Cox, Mark Sulkowski, Jeremy Sugarman
JOURNAL: Clin Infect Dis. 2020 Dec 31;71(11):2986-2990. doi: 10.1093/cid/ciaa640.
Abstract
Despite the existence of established treatments for hepatitis C virus (HCV), more effective means of preventing infection, such as a vaccine, are arguably needed to help reduce substantial global morbidity and mortality. Given the expected challenges of developing such a vaccine among those at heightened risk of infection, controlled human infection studies seem to be a promising potential approach to HCV vaccine development, but they raise substantial ethical and practical concerns. In this article, we describe some of the challenges related to the possibility of using controlled human infection studies to accelerate HCV vaccine development. The related ethical and practical concerns require further deliberation before such studies are planned and implemented.
For the full article, click here.
For a link to the abstract, click here.
